A protein phosphatase 1 specific phos phatase ta rgeting p eptide (PhosTAP) to identify the PP1 phosphatome
- PMID: 39446389
- PMCID: PMC11536154
- DOI: 10.1073/pnas.2415383121
A protein phosphatase 1 specific phos phatase ta rgeting p eptide (PhosTAP) to identify the PP1 phosphatome
Abstract
Phosphoprotein phosphatases (PPPs) are the key serine/threonine phosphatases that regulate all essential signaling cascades. In particular, Protein Phosphatase 1 (PP1) dephosphorylates ~80% of all ser/thr phosphorylation sites. Here, we developed a phosphatase targeting peptide (PhosTAP) that binds all PP1 isoforms and does so with a stronger affinity than any other known PP1 regulator. This PhosTAP can be used as a PP1 recruitment tool for Phosphorylation Targeting Chimera (PhosTAC)-type recruitment in in vitro and cellular experiments, as well as in phosphoproteomics experiments to identify PP1-specific substrates and phosphosites. The latter is especially important to further our understanding of cellular signaling, as the identification of substrates and especially phosphosites that are targeted by specific phosphatases lags behind that of their kinase counterparts. Using PhosTAP-based proteomics, we show that, counter to our current understanding, many PP1 regulators are also substrates, that the number of residues between regulator PP1-binding and phosphosites vary significantly, and that PP1 counteracts the activities of mitotic kinases. Finally, we also found that Haspin kinase is a direct substrate of PP1 and that its PP1-dependent dephosphorylation modulates its activity during anaphase. Together, we show that PP1-specific PhosTAPs are a powerful tool for +studying PP1 activity in vitro and in cells.
Keywords: phosphatase targeting peptide (PhosTAP); phosphoprotein phosphatases (PPP); protein engineering; protein phosphatase 1 (PP1); protein–protein interactions.
Conflict of interest statement
Competing interests statement:The authors declare no competing interest.
Figures
References
-
- Williams G. H., Stoeber K., The cell cycle and cancer. J. Pathol. 226, 352–364 (2012). - PubMed
-
- Nairn A. C., et al. , The role of DARPP-32 in the actions of drugs of abuse. Neuropharmacology 47, 14–23 (2004). - PubMed
-
- Fontanillo M., Köhn M., Phosphatases: Their roles in cancer and their chemical modulators. Adv. Exp. Med. Biol. 917, 209–240 (2016). - PubMed
MeSH terms
Substances
Grants and funding
- R01 GM144379/GM/NIGMS NIH HHS/United States
- R35GM119455/HHS | NIH | National Institute of General Medical Sciences (NIGMS)
- R01NS124666/HHS | NIH | National Institute of Neurological Disorders and Stroke (NINDS)
- R01 GM144483/GM/NIGMS NIH HHS/United States
- R01 GM134683/GM/NIGMS NIH HHS/United States
- R01GM144379/HHS | NIH | National Institute of General Medical Sciences (NIGMS)
- R35 GM119455/GM/NIGMS NIH HHS/United States
- P41 GM103393/GM/NIGMS NIH HHS/United States
- R01 NS124666/NS/NINDS NIH HHS/United States
- R01GM134683/HHS | NIH | National Institute of General Medical Sciences (NIGMS)
- P30 CA023108/CA/NCI NIH HHS/United States
- R01 NS091336/NS/NINDS NIH HHS/United States
LinkOut - more resources
Full Text Sources
